PARIS: A blockbuster anti-obesity and diabetes drug may value as little as US$3 monthly to fabricate as soon as it goes off patent later this month, researchers mentioned on Friday (Mar 6), offering a serious alternative to spice up well being in low and middle-income nations.
Semaglutide, the lively molecule in Novo Nordisk’s Ozempic and Wegovy treatments, results in appreciable weight reduction in sufferers and thus can present main assist in managing diabetes and different medical issues associated to weight problems.
Semaglutide will lose patent safety in nations similar to Brazil, China and India later this month, and researchers recognized 150 nations the place it was by no means patented.
Utilizing pricing data from different medicines that just lately went off patent, researchers in Britain, South Africa and New Zealand calculated the potential generic manufacturing worth for semaglutide.
They estimated it’s going to value as little as US$3 to provide a month’s provide of semaglutide, which in its branded kind sells for round US$200 a month in the USA.
Dr Samuel Cross of Imperial School London, one of many research’s authors, famous that weight problems and diabetes are continual ailments that enhance the danger of stroke, diabetes, coronary heart illness, kidney failure and most cancers.
“If generic manufacturing reduces costs to sustainable ranges, thousands and thousands extra individuals may entry therapy,” he mentioned.
